Literature DB >> 14567016

A historical perspective on colorectal liver metastases and peritoneal carcinomatosis: similar results, different treatments.

Philippe Gertsch1.   

Abstract

Similarities between peritoneal carcinomatosis and liver secondaries allow the oncologist to regard the peritoneum as an intraabdominal structure that can, like the liver, be resected with curative intent when disseminated disease has occurred. The possibility for cure of peritoneal carcinomatosis by cytoreductive surgery and IPHC must now be recognized. However, convincing data from controlled studies will be required for rapid general acceptance of this treatment, bringing, as a consequence, a chance of cure to a larger number of patients with a desperate prognosis. This fact, together with a scarcity of patients with peritoneal carcinomatosis eligible for definitive treatment, emphasizes the need for cooperative studies between centers of reference.

Entities:  

Mesh:

Year:  2003        PMID: 14567016     DOI: 10.1016/s1055-3207(03)00046-2

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  10 in total

1.  Cytoreductive surgery and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colonic origin: outcomes after 7 years' experience of a new centre for peritoneal surface malignancies.

Authors:  Pedro Bretcha-Boix; Jose Farré-Alegre; Manuel Sureda; Carlos Dussan; Juan José Pérez Ruixo; Antonio Brugarolas Masllorens
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

Review 2.  Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.

Authors:  Manuel J Koppe; Otto C Boerman; Wim J G Oyen; Robert P Bleichrodt
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

Review 3.  Management of peritoneal carcinomatosis from colorectal cancer.

Authors:  Chukwuemeka U Ihemelandu; Perry Shen; John H Stewart; Konstantinos Votanopoulos; Edward A Levine
Journal:  Semin Oncol       Date:  2011-08       Impact factor: 4.929

4.  Metastatic colorectal cancer: survival comparison of hepatic resection versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Aaron U Blackham; Gregory B Russell; John H Stewart; Konstantinos Votanopoulos; Edward A Levine; Perry Shen
Journal:  Ann Surg Oncol       Date:  2014-03-11       Impact factor: 5.344

5.  Surgical management of colorectal cancer metastases to the liver: multimodality approach and a single institutional experience.

Authors:  Aaron U Blackham; Katrina Swett; Edward A Levine; Perry Shen
Journal:  Colorectal Cancer       Date:  2013-02

6.  A new standard of care for the management of peritoneal surface malignancy.

Authors:  F Mohamed; T Cecil; B Moran; P Sugarbaker
Journal:  Curr Oncol       Date:  2011-04       Impact factor: 3.677

7.  Surgical management of carcinomatosis from colorectal cancer.

Authors:  Paul H Sugarbaker
Journal:  Clin Colon Rectal Surg       Date:  2005-08

8.  Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases.

Authors:  Reza Kianmanesh; Stefano Scaringi; Jean-Marc Sabate; Benjamin Castel; Nathalie Pons-Kerjean; Benoit Coffin; Jean-Marie Hay; Yves Flamant; Simon Msika
Journal:  Ann Surg       Date:  2007-04       Impact factor: 12.969

9.  Cytoreductive surgery plus hyperthermic perioperative chemotherapy for selected patients with peritoneal metastases from colorectal cancer: a new standard of care or an experimental approach?

Authors:  Paul H Sugarbaker
Journal:  Gastroenterol Res Pract       Date:  2012-07-19       Impact factor: 2.260

Review 10.  Role of multi-modality therapy in peritoneal carcinomatosis and visceral metastasis: a case report and review of the literature.

Authors:  Diego Vicente; Itzhak Avital; Alexander Stojadinovic
Journal:  World J Surg Oncol       Date:  2015-06-30       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.